Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082960 | 0.84 | NPC1 (0.55) | TGM2NPC1RAB9AKMT2ALMNA | |
| SCHEMBL18636751 | 0.80 | TGM2 (0.44) | TGM2NPC1RAB9AKMT2AMAPT | |
| SCHEMBL5797683 | 0.80 | NPC1 (0.42) | NPC1RAB9AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5797631 | 0.80 | RAB9A (0.42) | NPC1RAB9AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL25976165 | 0.77 | MAPK8 (0.44) | NPC1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL5797688 | 0.74 | NPC1 (0.40) | NPC1RAB9AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL9634503 | 0.74 | TGM2 (0.44) | TGM2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL959540 | 0.74 | TGM2 (0.69) | TGM2NPC1RAB9AKMT2AMAPT | |
| SCHEMBL29004445 | 0.73 | SMN1; SMN2 (0.61) | TGM2NPC1RAB9AKMT2AMAPT | |
| SCHEMBL6581126 | 0.72 | MMP13 (0.55) | TGM2NPC1RAB9AKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011092293-A2 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, CRH | TGM2 3401/4885NPC1 1318/4885RAB9A 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.